TECHWIRE 30
(CIX: WRAL30)  996.45  down arrow-8.5  (-0.85 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Apple)  524.75  down arrow-6.95  (-1.31 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: QUINTILES)  49.47  down arrow-0.48  (-0.96 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: BASF SE)  112.59  down arrow-0.25  (-0.22 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: BioCryst)  8.55  down arrow-0.65  (-7.07 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: BioDelivery)  8.66  up arrow+0.19  (2.24 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: CEMP)  9.92  down arrow-0.49  (-4.71 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Cisco Systems)  23.50  down arrow-0.02  (-0.09 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  51.04  down arrow-7.01  (-12.08 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: DARA)  1.88  up arrow+0.05  (2.73 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: EMC CORPORATION)  25.91  down arrow-0.85  (-3.18 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Extreme Networks)  5.70  down arrow-0.09  (-1.55 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Facebook)  61.36  down arrow-1.67  (-2.65 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: GLAXOSMITHKLINE)  55.14  down arrow-0.16  (-0.29 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: GOOG)  526.94  down arrow-7.87  (-1.47 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: IBM)  191.73  down arrow-0.42  (-0.22 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NY: LH)  99.85  down arrow-0.53  (-0.53 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: Lenovo Group)  22.76  down arrow-0.43  (-1.85 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: MRK)  57.50  down arrow-0.27  (-0.47 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Microsoft Corp)  39.69  down arrow-0.3  (-0.75 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: NetApp)  35.87  down arrow-0.18  (-0.49 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: NOVARTIS AG)  86.17  down arrow-0.39  (-0.45 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: Novozymes A/S)  46.99  up arrow+0.98  (2.13 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: PFIZER)  30.92  down arrow-0.08  (-0.26 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Pozen)  9.22  down arrow-0.03  (-0.32 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: RED HAT)  50.05  down arrow-0.85  (-1.67 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: BBRY)  7.36  up arrow+0.07  (0.96 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Salix)  109.95  up arrow+0.88  (0.81 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: SQI)  26.18  down arrow-0.8  (-2.97 %)  Updated: 08:10 PM EDT, Apr 23 2014

Posts tagged “Novartis”

August 29, 2012

Premium Lock Novartis smoker's cough drug beats GSK's Advair in trial

Lung disease Patients taking Novartis's QVA149 were able to expel more air from their lungs in one second than those receiving Glaxo's best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial.

August 29, 2012

Premium Lock Novartis experimental heart-failure drug shows promise

Heart research If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients.

August 7, 2012

Premium Lock Novartis funds $20M cancer facility at U. of Pennsylvania

Cancer research In exchange for the funding, the drug giant gains rights to the university's cancer technology that utilizes manipulated immune system stem cells.

June 19, 2012

Premium Lock Novartis, GSK win big biodefense center contracts

Pandemic Novartis along with Duke and NCSU will create a center for biodefense and to combat pandemic influenza in Holly Springs under a $60 million contract with the U.S. Department of Health and Human Services. GSK will work with Texas A&M on a $176 million deal.

Updated December 12, 2011

Premium Lock NCSU scientists to help spread new Novartis vaccine technology

NC biotech group hails formal dedication of the massive $1 billion Novartis plant in Holly Springs.

Novartis plant in Holly Springs Novartis plant in Holly Springs

December 8, 2011

Premium Lock Novartis drug plant in Wilson on FDA warning list

Novartis The U.S. Food and Drug Administration is taking Novartis CEO Joseph Jimenez to task with a warning letter that cites three of the company's manufacturing facilities for "significant violations" at the company's generics drug unit Sandoz.

November 4, 2011

Premium Lock Life science awards go to PPD, Novartis, Steve Burrill

Life science Scrips, an international life science media and related services firm based in the U.K., honors PPD with two awards, Novartis with three, and names Burrill its lifetime achievement winner.

Updated October 25, 2011

Premium Lock Novartis to cut 2,000 jobs, close 3 European plants

The drug giant, which operates a huge vaccine production and research facility in Holly Springs, says some jobs will be moved to the US as well as China and India.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 20, 2011

Premium Lock Novartis: 'Contagion' is fiction but threat is real

The movie "Contagion" is fiction, but ask Novartis executive Russell Thirsk and he'll tell you the threats it depicts are quite real.

Click here to open the YouTube video in a new window.

September 6, 2011

Premium Lock Novartis fights patent rejection in Indian court

Novartis In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec.

Tags: Novartis
April 19, 2011

Premium Lock Novartis earnings, sales top analysts' expectations

Novartis plant in Holly Springs Net income falls 6 percent but overall sales increase 16 percent from a year ago.

January 24, 2011

Premium Lock Novartis bids $470M for California-based cancer diagnostic firm

Novartis The Swiss drug maker, which is building a huge vaccine production plant in Holy Springs, is buying Genoptix.

December 22, 2010

Premium Lock Novartis to add 100 jobs, facilities at Holly Springs plant

The global life sciences firm will receive up to $3.7 million in state tax incentives for the expansion.

Novartis plant in Holly Springs Novartis plant in Holly Springs

November 16, 2010

Premium Lock Report: Novartis looking to buy as cash improves

Novartis The company is paying down debt from its Alcon purchase and looks to be debt-free in four years, the Financial Times said.

Tags: Novartis
Updated July 1, 2010

Premium Lock What pandemic? $260 million worth of H1N1 vaccine to go up in smoke

H1N1 A whopping 40 million does of the vaccine expires – and another 30 million doses are likely to be unused, federal government says. GSK, Novartis were among the big H1N1 vaccine providers.

Updated April 16, 2010

Premium Lock FDA slaps GSK, Novartis, Astellas for ad, Web claims

GSK Letters sent to the three companies concerned claims made for cancer, pain and bladder-control drugs.

Updated February 22, 2010

Premium Lock Viamet Pharmaceuticals signs license deal with Novartis topping $200M

Morrisville-based firm, which was co-founded by UNC-CH Chancellor Holden Thorp, will work with venture arm of Swiss drug giant in researching potential metal-based enzyme inhibitors.

Viamet Viamet

January 26, 2010

Premium Lock Novartis, which is building $1 billion plant in Holly Springs, names new CEO

Drug giant reports strong earnings. It also will pay a $185 million fine in case involving the marketing of its epilepsy drug Trileptal.

Novartis CEO Joe Jimenez, left, and Chairman Daniel Vasella Novartis CEO Joe Jimenez, left, and Chairman Daniel Vasella

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll